Q-omics provides the consensus-scored LOXHD1 profile across patient tissues and cancer cell-line models. LOXHD1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LOXHD1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, LOXHD1 RNA expression shows 15,038 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUAD, and THYM as cancer lineages where LOXHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LOXHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LOXHD1 survival associations across molecular data types. LOXHD1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LOXHD1 RNA expression–survival associations across cancer types. High LOXHD1 expression shows unfavorable associations in BLCA, LUSC, DLBC and CESC, but favorable associations in HNSC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for LOXHD1 RNA expression.
This table summarizes LOXHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LOXHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LOXHD1 shows lower tumor expression in LUAD, KIRP, LUSC and THCA and higher tumor expression in HNSC and LIHC. The LUAD box plot shows higher LOXHD1 RNA expression in normal versus tumor tissue (log2 FC = −0.707, t-test p < 0.001).
This table shows molecular features associated with LOXHD1 in patient tissues and cancer cell lines. In patient samples, LOXHD1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LOXHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
